1. Home
  2. PLG vs BNR Comparison

PLG vs BNR Comparison

Compare PLG & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Platinum Group Metals Ltd. (Canada)

PLG

Platinum Group Metals Ltd. (Canada)

HOLD

Current Price

$1.65

Market Cap

223.4M

Sector

N/A

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$14.70

Market Cap

179.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLG
BNR
Founded
2000
2014
Country
Canada
China
Employees
N/A
N/A
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
223.4M
179.7M
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
PLG
BNR
Price
$1.65
$14.70
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
1.4M
12.6K
Earning Date
04-10-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$111.65
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.35
$2.80
52 Week High
$4.04
$41.72

Technical Indicators

Market Signals
Indicator
PLG
BNR
Relative Strength Index (RSI) 43.67 35.06
Support Level $1.65 $7.99
Resistance Level $1.73 $18.59
Average True Range (ATR) 0.11 0.82
MACD -0.01 -0.16
Stochastic Oscillator 25.00 4.66

Price Performance

Historical Comparison
PLG
BNR

About PLG Platinum Group Metals Ltd. (Canada)

Platinum Group Metals Ltd is a development-stage company, conducts work on mineral properties it has staked or acquired by way of option agreements in the Republic of South Africa. Key metals of economic interest on the company's mineral properties include platinum, palladium, rhodium, gold, copper, and nickel. The company operates in one segment, the development of the Waterberg Project in South Africa, and geographically in Canada and South Africa.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: